Investigating biomarkers to improve outcomes in early psychosis treatment
2/5 Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services (BICEPS)
This study is looking at how certain biological signs and symptoms can help predict how young adults with early psychosis, like schizophrenia or bipolar disorder, will do over time, so we can create better, personalized treatment plans for them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10877885 on NIH RePORTER |
What this research studies
This research focuses on understanding how specific biological markers and clinical features can predict the outcomes of early psychosis in young adults. By analyzing data from patients aged 18-35 with conditions like schizophrenia and bipolar disorder, the study aims to categorize these individuals into different biotypes based on their EEG, eye movement tests, and cognitive assessments. This categorization will help tailor treatment plans and improve the effectiveness of coordinated specialty care services. Patients will be followed up at 1, 6, and 12 months to assess their progress and refine treatment strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are young adults aged 18-35 who are experiencing early symptoms of psychosis, including those with schizophrenia or bipolar disorder.
Not a fit: Patients outside the age range of 18-35 or those not experiencing early psychosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment plans for individuals experiencing early psychosis.
How similar studies have performed: Previous research has shown promise in using biomarkers to predict outcomes in psychosis, indicating that this approach has potential for success.
Where this research is happening
Chicago, United States
- University of Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Gershon, Elliot S — University of Chicago
- Study coordinator: Gershon, Elliot S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.